S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.65%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.65%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.65%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.65%)
Log in

NASDAQ:INFIInfinity Pharmaceuticals Stock Price, Forecast & News

$0.94
-0.03 (-3.09 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.89
Now: $0.94
$0.97
50-Day Range
$0.69
MA: $0.99
$1.45
52-Week Range
$0.60
Now: $0.94
$1.80
Volume101,686 shs
Average Volume205,062 shs
Market Capitalization$54.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Read More
Infinity Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 million
Book Value$0.14 per share

Profitability

Net Income$-47,060,000.00
Net Margins-1,542.85%

Miscellaneous

Employees25
Market Cap$54.01 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.


Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

How has Infinity Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INFI shares have decreased by 6.9% and is now trading at $0.9403. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Infinity Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Infinity Pharmaceuticals.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Infinity Pharmaceuticals.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its earnings results on Tuesday, March, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.28 million. Infinity Pharmaceuticals had a negative return on equity of 197.48% and a negative net margin of 1,542.85%. View Infinity Pharmaceuticals' earnings history.

What price target have analysts set for INFI?

4 brokerages have issued 12-month target prices for Infinity Pharmaceuticals' stock. Their forecasts range from $1.50 to $3.50. On average, they expect Infinity Pharmaceuticals' share price to reach $2.67 in the next twelve months. This suggests a possible upside of 183.6% from the stock's current price. View analysts' price targets for Infinity Pharmaceuticals.

Has Infinity Pharmaceuticals been receiving favorable news coverage?

Media coverage about INFI stock has trended very negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutInfinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 30,500 shares, a drop of 26.3% from the February 27th total of 41,400 shares. Based on an average daily volume of 143,300 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX), AVEO Pharmaceuticals (AVEO) and Halozyme Therapeutics (HALO).

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)
  • Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)
  • Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)
  • Ms. Melissa Hackel, VP of Fin.

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $0.94.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $54.01 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe. View additional information about Infinity Pharmaceuticals.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is http://www.infi.com/.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel